Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Clinical Research Training in Hematology Hall of Fame

Presentations

EHA-ISHBT Hematology Tutorial

Session 1: Congenital and acquired neutropenias and bone marrow failure  

Lecture:  F Fioredda (here)
Clinical case: F Fioredda (here)
Self-assessment cases:
Speaker 1: M Mahapatra (Permission not granted)
Speaker 2: A Khurana (here)
Session 2: Hemolytic Anemia

Lecture:  L Da Costa (Not available)
Clinical case: L…

Publications

Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, Lassila R, Leebeek FWG, Makris M, Owaidah T, Sholzberg M, Tiede A, Werring DJ, van der Worp HB,…

Multiple Myeloma

The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position 
Company 
Priority points 
Corporate Level 

1 
Johnson & Johnson  
1. 488,82  
Platinum  

2 
Bristol Myers Squibb  
1.

What an EHA Innovation Grant supports

Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.

Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast

“Congratulations – your abstract was accepted for the upcoming EHA congress”.